Initial Treatment for Inflammatory Myositis

Treatment Algorithm for Adult Patients

• The American College of Physicians recommends initial treatment with high-dose corticosteroids (0.5-1 mg/kg/day, typically 60-80 mg/day) concurrent with a steroid-sparing agent such as methotrexate, azathioprine, or mycophenolate mofetil for adult patients with idiopathic inflammatory myositis 1, 2
• Begin prednisone at 0.5-1 mg/kg per day (typically 60-80 mg daily as a single dose) and concurrently initiate a steroid-sparing immunosuppressive agent, such as methotrexate, azathioprine, or mycophenolate mofetil 1, 2, 3

Corticosteroid Tapering Schedule

• Begin tapering corticosteroids after 2-4 weeks depending on patient response, tapering by 10 mg every 2 weeks until reaching 30 mg/day, then by 5 mg every 2 weeks until reaching 20 mg/day, and finally by 2.5 mg every 2 weeks 1, 3

Treatment for Severe Disease

• For patients with severe myositis or extensive extramuscular involvement, add high-dose methylprednisolone, and consider additional therapies such as cyclophosphamide or cyclosporine 1, 2

Treatment for Juvenile Dermatomyositis

• For uncomplicated juvenile dermatomyositis, begin corticosteroids at 2 mg/kg up to a maximum of 60 mg/day and add subcutaneous methotrexate at treatment onset at 15 mg/m² once weekly, tapering corticosteroids after 2-4 weeks based on response 1, 2

Monitoring and Follow-up

• Monitor muscle enzyme levels and inflammatory markers, and use MRI with T1-weighted, T2-weighted, and fat suppression techniques to monitor treatment response 1, 2

Special Considerations

• Management of immune-mediated necrotizing myopathy (IMNM) is similar to dermatomyositis/polymyositis with corticosteroids and immunosuppressants, and may require more aggressive therapy due to potentially severe weakness 1, 4

Common Pitfalls

• Failure to screen for malignancy in adult patients, especially with dermatomyositis, is a common pitfall, as is inadequate initial dosing of corticosteroids and delaying initiation of steroid-sparing agents 2, 3

Methylprednisolone Pulse Therapy in Inflammatory Myositis

Indications and Treatment

• For adult patients with severe myositis, high-dose methylprednisolone pulses should be administered in addition to other immunosuppressive agents, as recommended by the Mayo Clinic Proceedings 5
• Pulse therapy is indicated for patients with extensive extramuscular organ involvement, as suggested by the Mayo Clinic Proceedings 5
• The British Journal of Dermatology recommends typical pulse dosing involves intravenous methylprednisolone 10-20 mg/kg or 250-1000 mg given on 1-5 consecutive days 6

Combination Therapy

• For optimal outcomes, pulse methylprednisolone should be combined with other immunosuppressive agents, such as intravenous immunoglobulin (IVIG), as recommended by the Mayo Clinic Proceedings and Annals of the Rheumatic Diseases 5, 7
• Combination therapies including cyclophosphamide, rituximab, and cyclosporine may also be effective, as suggested by the Mayo Clinic Proceedings 5

Potential Adverse Effects

• Common complications of long-term corticosteroid use include excessive weight gain, hypertension, stretch marks, growth delay in children, cataracts, diabetes, dyslipidemia, and corticosteroid-induced myopathy, as reported by the Mayo Clinic Proceedings 5

Special Considerations

• In checkpoint inhibitor-induced myositis, high-dose systemic glucocorticoids are the first-line treatment, with approximately 10% of reported patients receiving intravenous pulses of methylprednisolone, as reported by the Annals of the Rheumatic Diseases 7

Steroid Therapy Guidelines for Inflammatory Myositis

Initial Treatment Approach

• Initiating a steroid‑sparing immunosuppressive agent (e.g., methotrexate, azathioprine, or mycophenolate mofetil) concurrently with high‑dose prednisone (0.5–1 mg/kg/day) improves long‑term outcomes by reducing cumulative steroid exposure and associated morbidity; evidence is based on observational data. 8

Corticosteroid Tapering Strategy

• After 2–4 weeks of clinical response, prednisone should be tapered to a maintenance dose of ≤10 mg/day using a stepwise reduction schedule; this recommendation reflects expert consensus. [9][10]

Management of Severe or Refractory Disease

• For severe myositis or extensive extramuscular involvement, high‑dose intravenous methylprednisolone pulses (10–20 mg/kg or 250–1000 mg daily for 1–5 days) are advised. 8
• Intravenous immunoglobulin (IVIG) is supported by controlled studies in dermatomyositis and shown to be effective in polymyositis. 8
• Cyclophosphamide is recommended for life‑threatening disease manifestations. 8
• Rituximab may be employed for refractory cases when other agents fail. 8
• Cyclosporine is presented as an alternative immunosuppressive option. 8

Monitoring and Prevention of Steroid‑Related Complications

• Routine bone health assessment with DEXA scans is advised to detect osteoporosis early. 8
• Calcium and vitamin D supplementation should be provided to all patients on long‑term glucocorticoids. 8
• Bisphosphonate therapy is indicated if osteoporosis develops during treatment. 8
• Pneumocystis jirovecii prophylaxis with trimethoprim‑sulfamethoxazole is recommended for patients receiving ≥20 mg prednisone daily for ≥4 weeks. 8

Checkpoint Inhibitor‑Induced Myositis

• High‑dose systemic glucocorticoids remain first‑line therapy for checkpoint inhibitor‑associated myositis, with approximately 10 % of patients requiring intravenous methylprednisolone pulses. [9][11]
• A task‑force recommendation advises avoiding methylprednisolone pulses in non‑life‑threatening cases to prevent potential impairment of antitumor immune responses. (expert consensus) [9][11]

Management of Checkpoint‑Inhibitor‑Related Inflammatory Myositis

Diagnostic Evaluation

• Laboratory panel: Obtain serum creatine kinase, aldolase, AST, ALT, and LDH to quantify muscle inflammation in patients with suspected myositis. 12
• Cardiac work‑up: Measure troponin I (more specific than troponin T), perform ECG and transthoracic echocardiography to exclude myocarditis, which raises mortality to ≈ 20 % versus < 10 % in idiopathic myositis. 13
• Inflammatory markers: Check erythrocyte sedimentation rate and C‑reactive protein at baseline. 12
• Autoantibody screening: Test for myositis‑specific antibodies and for anti‑acetylcholine‑receptor/anti‑striational antibodies to identify myasthenia gravis overlap. 12
• Urinalysis: Perform dip‑stick testing to detect hematuria or myoglobinuria indicative of rhabdomyolysis. 12
• Physical examination:
  
  • Assess proximal muscle strength; weakness is more common than pain. 12
  • Inspect skin for Gottron’s papules or heliotrope rash, recognizing that dermatomyositis signs may be absent early. 13
  • Evaluate bulbar function (dysphagia, dysarthria, dysphonia) as markers of severe disease requiring aggressive therapy. 13
  • Test respiratory muscle performance because respiratory involvement can be life‑threatening. 13
  • Screen for cardiac symptoms (dyspnea, palpitations, chest pain, syncope) that suggest myocarditis. 13
• Electrodiagnostic studies: Use EMG when a neurologic overlap syndrome is suspected. 12
• Muscle biopsy: Reserve for cases with uncertain diagnosis or suspected overlap syndromes. 12

Initial Treatment Algorithm

Mild Disease (Grade 1)

• Provide acetaminophen or NSAIDs for myalgia when no contraindications exist. 12
• If creatine kinase is elevated together with weakness, start prednisone 0.5 mg/kg/day and manage the patient as moderate disease (Grade 2). 12

Moderate Disease ( Grade 2 )

• Checkpoint‑inhibitor management: Hold immune‑checkpoint therapy temporarily; resume only after symptoms are controlled and prednisone is tapered below 10 mg/day. 12
• Glucocorticoid therapy: Begin prednisone 0.5–1 mg/kg/day (typically 60–80 mg daily). 12
• Specialist referral: Promptly refer to rheumatology or neurology for co‑management. 12
• Potential permanent discontinuation: In most patients with objective evidence (elevated enzymes, abnormal EMG/MRI/biopsy), checkpoint inhibitors may need to be stopped permanently. 14

Severe Disease ( Grades 3–4 )

• Checkpoint‑inhibitor cessation: Permanently discontinue checkpoint inhibitors when myocardial involvement is present. 14

Monitoring Strategy

• Cardiac surveillance: Repeat troponin and ECG whenever cardiac symptoms develop to detect evolving myocarditis. 13

Critical Pitfalls to Avoid

• Myocarditis is the leading cause of death in checkpoint‑inhibitor‑related myositis; systematic cardiac evaluation is mandatory in every suspected case. 13
• Normal cardiac enzyme levels do not exclude myocarditis; maintain a high index of suspicion. 13
• Cardiac MRI should be performed when clinical suspicion, troponin elevation, or ECG abnormalities are present. 13
• Myasthenia gravis overlap occurs in ~12.5 % of cases; specific autoantibody testing is required to identify it. 13

Special Population Considerations

• Checkpoint‑inhibitor‑related myositis typically manifests early (median ≈ 25 days after therapy start), frequently co‑occurs with myocarditis and/or myasthenia gravis, and carries higher mortality than idiopathic myositis. 13
• Approximately 10 % of affected patients require IV methylprednisolone pulse therapy. 13
• Up to 20 % may need intravenous immunoglobulin, and about 10 % may require plasma exchange for refractory disease. 13